Elan Pharmaceuticals

Elan Pharmaceuticals is a neuroscientific technology company headquartered in Ireland, engaged in the research, development, and sale of pharmaceutical products. The company was founded in 1986 and is headquartered in South San Francisco, California. It discovers, develops, manufactures, and markets treatments for neurodegenerative diseases, autoimmune diseases, and severe pain. All drugs produced by the company are delivered to a wide range of pharmaceutical companies, from large global organizations to development-stage firms. Through its pharmaceutical technology, the company has developed improved formulations for 35 products, which have been launched in more than 100 countries. The company also sells its product TYSABRI in the United States, the European Union, Switzerland, Canada, and Australia. Its R&D, marketing, and manufacturing operations are located in both Ireland and the United States. Elan's headquarters is in Dublin, Ireland. In 2013, Elan Pharmaceuticals, Inc. was acquired by Perrigo Co. (PRGO), an American over-the-counter drug manufacturer, for $8.6 billion, gaining a low tax base for international expansion.